Logo image of CURI

CURIOSITYSTREAM INC (CURI) Stock Fundamental Analysis

USA - NASDAQ:CURI - US23130Q1076 - Common Stock

5.18 USD
-0.03 (-0.58%)
Last: 9/25/2025, 8:00:00 PM
5.18 USD
0 (0%)
After Hours: 9/25/2025, 8:00:00 PM
Fundamental Rating

4

Overall CURI gets a fundamental rating of 4 out of 10. We evaluated CURI against 80 industry peers in the Entertainment industry. While CURI seems to be doing ok healthwise, there are quite some concerns on its profitability. CURI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CURI has reported negative net income.
In the past year CURI had a positive cash flow from operations.
In the past 5 years CURI always reported negative net income.
CURI had negative operating cash flow in 4 of the past 5 years.
CURI Yearly Net Income VS EBIT VS OCF VS FCFCURI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -6.07%, CURI is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
CURI's Return On Equity of -9.57% is in line compared to the rest of the industry. CURI outperforms 51.25% of its industry peers.
Industry RankSector Rank
ROA -6.07%
ROE -9.57%
ROIC N/A
ROA(3y)-32.15%
ROA(5y)-36.84%
ROE(3y)-44.33%
ROE(5y)-58.97%
ROIC(3y)N/A
ROIC(5y)N/A
CURI Yearly ROA, ROE, ROICCURI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

With a decent Gross Margin value of 53.07%, CURI is doing good in the industry, outperforming 62.50% of the companies in the same industry.
In the last couple of years the Gross Margin of CURI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CURI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.26%
GM growth 5YN/A
CURI Yearly Profit, Operating, Gross MarginsCURI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

CURI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CURI has been increased compared to 1 year ago.
CURI has more shares outstanding than it did 5 years ago.
CURI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CURI Yearly Shares OutstandingCURI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CURI Yearly Total Debt VS Total AssetsCURI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CURI has an Altman-Z score of 1.37. This is a bad value and indicates that CURI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CURI (1.37) is comparable to the rest of the industry.
CURI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 1.37
ROIC/WACCN/A
WACC8.8%
CURI Yearly LT Debt VS Equity VS FCFCURI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

CURI has a Current Ratio of 1.66. This is a normal value and indicates that CURI is financially healthy and should not expect problems in meeting its short term obligations.
CURI's Current ratio of 1.66 is fine compared to the rest of the industry. CURI outperforms 67.50% of its industry peers.
CURI has a Quick Ratio of 1.66. This is a normal value and indicates that CURI is financially healthy and should not expect problems in meeting its short term obligations.
CURI has a Quick ratio of 1.66. This is in the better half of the industry: CURI outperforms 70.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
CURI Yearly Current Assets VS Current LiabilitesCURI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 87.50% over the past year.
CURI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.02%.
CURI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.47% yearly.
EPS 1Y (TTM)87.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
Revenue 1Y (TTM)11.02%
Revenue growth 3Y-10.47%
Revenue growth 5YN/A
Sales Q2Q%53.38%

3.2 Future

Based on estimates for the next years, CURI will show a very strong growth in Earnings Per Share. The EPS will grow by 50.40% on average per year.
CURI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.02% yearly.
EPS Next Y97.17%
EPS Next 2Y48.74%
EPS Next 3Y33.56%
EPS Next 5Y50.4%
Revenue Next Year34.3%
Revenue Next 2Y21.37%
Revenue Next 3Y18.56%
Revenue Next 5Y13.02%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CURI Yearly Revenue VS EstimatesCURI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
CURI Yearly EPS VS EstimatesCURI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

CURI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 101.57, the valuation of CURI can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CURI is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of CURI to the average of the S&P500 Index (22.64), we can say CURI is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 101.57
CURI Price Earnings VS Forward Price EarningsCURI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CURI is on the same level as its industry peers.
CURI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CURI is cheaper than 78.75% of the companies in the same industry.
Industry RankSector Rank
P/FCF 30.22
EV/EBITDA 24.78
CURI Per share dataCURI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

CURI's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as CURI's earnings are expected to grow with 33.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.74%
EPS Next 3Y33.56%

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 6.50%, CURI is a good candidate for dividend investing.
CURI's Dividend Yield is rather good when compared to the industry average which is at 20.19. CURI pays more dividend than 93.75% of the companies in the same industry.
CURI's Dividend Yield is rather good when compared to the S&P500 average which is at 2.38.
Industry RankSector Rank
Dividend Yield 6.5%

5.2 History

CURI does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
CURI Yearly Dividends per shareCURI Yearly Dividends per shareYearly Dividends per share 2024 2025 0.05 0.1 0.15 0.2 0.25

5.3 Sustainability

CURI has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-322.61%
EPS Next 2Y48.74%
EPS Next 3Y33.56%
CURI Yearly Income VS Free CF VS DividendCURI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

More info and screens

CURIOSITYSTREAM INC

NASDAQ:CURI (9/25/2025, 8:00:00 PM)

After market: 5.18 0 (0%)

5.18

-0.03 (-0.58%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners13.6%
Inst Owner Change65.24%
Ins Owners6.96%
Ins Owner Change2.22%
Market Cap300.08M
Analysts86
Price Target6.29 (21.43%)
Short Float %4.59%
Short Ratio2.85
Dividend
Industry RankSector Rank
Dividend Yield 6.5%
Yearly Dividend0.07
Dividend Growth(5Y)N/A
DP-322.61%
Div Incr Years1
Div Non Decr Years1
Ex-Date09-05 2025-09-05 (0.08)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)6.66%
Min Revenue beat(2)-0.09%
Max Revenue beat(2)13.4%
Revenue beat(4)2
Avg Revenue beat(4)1.87%
Min Revenue beat(4)-9.67%
Max Revenue beat(4)13.4%
Revenue beat(8)3
Avg Revenue beat(8)0.63%
Revenue beat(12)6
Avg Revenue beat(12)-2.69%
Revenue beat(16)7
Avg Revenue beat(16)-2.52%
PT rev (1m)9.07%
PT rev (3m)33.97%
EPS NQ rev (1m)12.5%
EPS NQ rev (3m)30%
EPS NY rev (1m)0%
EPS NY rev (3m)89.74%
Revenue NQ rev (1m)1.05%
Revenue NQ rev (3m)14.5%
Revenue NY rev (1m)0.6%
Revenue NY rev (3m)7.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 101.57
P/S 4.93
P/FCF 30.22
P/OCF 29.99
P/B 6.02
P/tB 14.11
EV/EBITDA 24.78
EPS(TTM)-0.09
EYN/A
EPS(NY)0.05
Fwd EY0.98%
FCF(TTM)0.17
FCFY3.31%
OCF(TTM)0.17
OCFY3.33%
SpS1.05
BVpS0.86
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.07%
ROE -9.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.07%
FCFM 16.32%
ROA(3y)-32.15%
ROA(5y)-36.84%
ROE(3y)-44.33%
ROE(5y)-58.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.26%
GM growth 5YN/A
F-Score7
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.47%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion 98.19%
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z 1.37
F-Score7
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)0.12%
Cap/Depr(5y)1.04%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
EPS Next Y97.17%
EPS Next 2Y48.74%
EPS Next 3Y33.56%
EPS Next 5Y50.4%
Revenue 1Y (TTM)11.02%
Revenue growth 3Y-10.47%
Revenue growth 5YN/A
Sales Q2Q%53.38%
Revenue Next Year34.3%
Revenue Next 2Y21.37%
Revenue Next 3Y18.56%
Revenue Next 5Y13.02%
EBIT growth 1Y57.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year144.08%
EBIT Next 3Y51.16%
EBIT Next 5Y26.01%
FCF growth 1Y131.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y131.29%
OCF growth 3YN/A
OCF growth 5YN/A